Comenius University Faculty of Medicine, 5th Department of Internal Medicine, University Hospital, Bratislava, Slovakia.
Medical Department, Exeltis, Bratislava, Slovakia.
Front Endocrinol (Lausanne). 2022 Nov 16;13:1067029. doi: 10.3389/fendo.2022.1067029. eCollection 2022.
The present study aims to evaluate the effect of myo-Inositol plus Selenium supplementation in patients affected by subclinical hypothyroidism.
One hundred and forty-eight patients were included in the study from 8 different centers of Slovakia, and treated for 6 months with a daily dose of 600 mg myo-Ins plus 83 mcg Se. The patients included at the enrollment were women of reproductive age (18-50), who exhibit values of TSH in the range 2.5-5 mU/l and positivity to antibodies TPO-Ab/TG-Ab, or otherwise values of TSH in the range 5-10 mU/l both with and without positivity to antibodies TPO-Ab/TG-Ab.
Patients affected by subclinical hypothyroidism exhibited a significant improvement of their condition when treated for 6 months with a combination of myo-Inositol and Selenium. The TSH values significantly ameliorated along with the index of autoimmunity and the thyroid status. In a sub-class of patients, the auto-antibody titer decreased after myo-inositol + Selenium administration. The treatment also induces a regularization of the menstrual cycle and a reduction of the cholesterol in the patients enrolled for the study. Furthermore, a significant improvement is observed in the perception of the symptoms associated with subclinical hypothyroidism over the treatment period.
A dietary supplementation with of myo-Inositol and Selenium in the treatment of patients affected by subclinical hypothyroidism exhibits a beneficial role in the recovery of TSH values, in the improvement of the symptoms associated to this condition and in the maintenance of the thyroid functions.The trial was approved by the Ethical Committee from National Institute of Endocrinology and Diabetology of Lubochna, Slovakia, date 18.12.2018, registration number: 3124/2018.
本研究旨在评估肌醇加硒补充剂对亚临床甲状腺功能减退症患者的影响。
从斯洛伐克的 8 个不同中心共纳入 148 例患者，每天接受 600mg 肌醇加 83μg 硒治疗 6 个月。纳入的患者为育龄期妇女（18-50 岁），其 TSH 值在 2.5-5mU/L 范围内，且 TPO-Ab/TG-Ab 抗体阳性，或 TSH 值在 5-10mU/L 范围内，无论 TPO-Ab/TG-Ab 抗体是否阳性。
亚临床甲状腺功能减退症患者在接受肌醇和硒联合治疗 6 个月后，病情明显改善。TSH 值、自身免疫指数和甲状腺功能均显著改善。在亚组患者中，肌醇+硒治疗后自身抗体滴度降低。治疗还可使患者的月经周期规律化，并降低胆固醇水平。此外，在治疗期间，患者对亚临床甲状腺功能减退症相关症状的感知也显著改善。
亚临床甲状腺功能减退症患者的肌醇和硒膳食补充治疗在恢复 TSH 值、改善与该疾病相关的症状以及维持甲状腺功能方面发挥有益作用。该试验得到了斯洛伐克卢博科纳国家内分泌学和糖尿病学研究所伦理委员会的批准，日期为 2018 年 12 月 18 日，注册号为 3124/2018。
